Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES, INC.ARE · Entity 419 | Director · Executive Chairman | September 11, 2026 | September 15, 2026 |
| Applied Therapeutics, Inc.APLT · Entity 67708 | Director | June 06, 2024 | June 07, 2024 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | March 15, 2019 | March 19, 2019 |
| Korro Bio, Inc.FREQ · Entity 6388 | Director | August 17, 2022 | August 19, 2022 |
| MeiraGTx Holdings plcMGTX · Entity 4734 | Director | June 07, 2022 | June 09, 2022 |
| TRex Bio, Inc.TRXB · Entity 184308 | Director | October 13, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXANDRIA REAL ESTATE EQUITIES, INC.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 597,724 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Purchase · Acquired 5,000 · Balance 597,724 F1: The shares were purchased at prices ranging from $49.38 to $49.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased at prices ranging from $49.38 to $49.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Applied Therapeutics, Inc.
Report date June 06, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 498,414 |
Reported balance
After 2024-06-06 transaction · row 1
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 45,000 · Balance 498,414 F1: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date.
Atara Biotherapeutics, Inc.
Report date March 15, 2019 · Filed March 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 888,355 |
Reported balance
After 2019-03-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-03-15 · Sale · Disposed 20,000 · Balance 888,355 F1: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $38.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by the Joel S. Marcus and Barbara A. Marcus Family Trust | 4,000 |
Reported balance
Holding disclosure · report date 2019-03-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 |
| Common StockSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2019-03-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $38.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein.
Korro Bio, Inc.
Report date August 17, 2022 · Filed August 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2030-06-10 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $18.63 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-06-16 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.14 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders
F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders
F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
MeiraGTx Holdings plc
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.25 · Expires 2032-06-07 | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F2: Each restricted share unit converts into one ordinary share upon vesting. F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
F2: Each restricted share unit converts into one ordinary share upon vesting.
F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
TRex Bio, Inc.
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,871 |
Reported balance
After 2026-10-13 transaction · row 1
1 source rowRow 1 · 2026-10-13 · Conversion · Acquired 41,871 · Balance 41,871 F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-13 · Conversion · Disposed 161,828 · Balance 0 F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intra-Cellular Therapies, Inc.
Report date April 02, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 1
1 source rowRow 1 · 2025-04-02 · Disposition to issuer · Disposed 48,238 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-04-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F3: Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
F3: Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
F6: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share.
F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.
F8: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2021 Filed Jun 15, 2021 21:02 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-21-040650 · doc4.xml · derivative · entry 6 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 21:02 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 18,289 | $42.27 | $773,076.03 |
DisclosureSEC source: 0001209191-21-040650 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 48,980 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.11 to $42.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 21:02 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 20,000 | $38.35 | $767,000.00 |
DisclosureSEC source: 0001209191-21-040650 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 67,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:48 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantRestricted Share Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006660 · edgar.xml · derivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon settlement. The restricted share units become settleable when the reporting person ceases to be a director. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 10, 2022 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2022. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 10, 2022 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2022. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:48 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001179110-21-006660 · edgar.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 10, 2022 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2022. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 23:19 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $19.70 | $0.00 |
DisclosureSEC source: 0001209191-21-038428 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-06-02 F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 3, 2021 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| May 27, 2021 Filed Jun 4, 2021 20:02 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionRestricted Stock Units · Derivative | 13,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038181 · doc4.xml · derivative · entry 5 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: On May 27, 2020, the reporting person was granted 13,767 restricted stock units, vesting on the first anniversary of the grant date (May 27, 2021). F4 · derivative.expiration_date: On May 27, 2020, the reporting person was granted 13,767 restricted stock units, vesting on the first anniversary of the grant date (May 27, 2021). Read SEC document |
| May 27, 2021 Filed Jun 4, 2021 20:02 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 13,767 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-038181 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 04, 2021 Filed May 5, 2021 20:22 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $180.41 | $902,050.00 |
DisclosureSEC source: 0001035443-21-000140 · wf-form4_162024610659003.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,597 F2 · price: The shares were sold at prices ranging from $180.40 to $180.49. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:22 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 15,000 | $180.33 | $2,704,950.00 |
DisclosureSEC source: 0001035443-21-000140 · wf-form4_162024610659003.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,597 F1 · price: The shares were sold at prices ranging from $180.19 to $180.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 23:24 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,071 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027056 · doc4.xml · derivative · entry 7 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,839 Underlying: Common Stock · 13,071 shares Expires 2029-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 13,071 shares subject to the options were vested as of April 13, 2021, with one thirty-sixth (1/36th) of the remaining shares subject to the options vesting each month thereafter, subject to the reporting person continuing to provide service through each such date. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 23:24 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,911 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001209191-21-027056 · doc4.xml · derivative · entry 6 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,911 shares Expires 2029-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options became fully vested on March 18, 2021. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 23:24 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,453 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027056 · doc4.xml · derivative · entry 5 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,453 shares Expires 2027-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options became fully vested on April 22, 2019. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 23:24 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 67,435 | $10.00 | $674,350.00 |
DisclosureSEC source: 0001209191-21-027056 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 98,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Shares held by family trust, of which the reporting person and his spouse are trustees. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 23:24 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 13,071 | $4.70 | $61,433.70 |
DisclosureSEC source: 0001209191-21-027056 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 31,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Shares held by family trust, of which the reporting person and his spouse are trustees. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 23:24 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 18,453 | $1.00 | $18,453.00 |
DisclosureSEC source: 0001209191-21-027056 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 18,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Shares held by family trust, of which the reporting person and his spouse are trustees. Read SEC document |
| April 14, 2021 Filed Sep 17, 2022 01:02 UTC Amendment | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,071 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050426 · doc4a.xml · derivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,389 Underlying: Common Stock · 13,071 shares Expires 2029-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 13,071 shares subject to the options were vested as of April 13, 2021, with one thirty-sixth (1/36th) of the remaining shares subject to the options vesting each month thereafter, subject to the reporting person continuing to provide service through each such date. F7 · balance_after: The Original Form 4 incorrectly reported the number of options beneficially owned following the reported transaction as 7,839 due to an administrative error. Read SEC document |
| April 14, 2021 Filed Sep 17, 2022 01:02 UTC Amendment | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 35,911 | $4.70 | $168,781.70 |
DisclosureSEC source: 0001209191-22-050426 · doc4a.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 67,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: The Original Form 4 incorrectly reported the number of shares acquired from an option exercise as 67,435 due to an administrative error. F5 · price: The Original Form 4 incorrectly reported the option exercise price for 35,911 shares of the issuer's common stock as $10 due to an administrative error. F2 · balance_after: This amount reflects the number of securities beneficially owned after the reported transactions on April 14, 2021. F3 · ownership.nature: Shares held by family trust, of which the reporting person and his spouse are trustees. Read SEC document |
| April 14, 2021 Filed Sep 17, 2022 01:02 UTC Amendment | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 13,071 | $10.00 | $130,710.00 |
DisclosureSEC source: 0001209191-22-050426 · doc4a.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 31,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The original Form 4 filed on April 16, 2021 (the "Original Form 4") incorrectly reported the option exercise price for 13,071 shares of the issuer's common stock as $4.7 due to an administrative error. F2 · balance_after: This amount reflects the number of securities beneficially owned after the reported transactions on April 14, 2021. F3 · ownership.nature: Shares held by family trust, of which the reporting person and his spouse are trustees. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 20:05 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-026637 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 47,269 F1 · kind: The reporting person transferred these shares as a gift to a family member. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 19:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | Tax withholdingCommon Stock | 12,395 | $164.30 | $2,036,498.50 |
DisclosureSEC source: 0001035443-21-000091 · wf-form4_161739226128274.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,597 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 19:38 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 21,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-21-000091 · wf-form4_161739226128274.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,992 Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:37 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionStock Option · Derivative | 37,116 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001127602-21-012232 · form4.xml · derivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,116 shares Expires 2029-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option became fully vested and exercisable on December 26, 2020. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:37 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Exercise / conversionCommon Stock | 37,116 | $3.37 | $125,080.92 |
DisclosureSEC source: 0001127602-21-012232 · form4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:45 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | Exercise / conversionStock Option (right to buy) · Derivative | 12,882 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001179110-21-003566 · edgar.xml · derivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,882 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option fully vested with respect to half of the total grant on March 4, 2016 and as to the remainder of the grant on March 4, 2017. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:45 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | Exercise / conversionOrdinary Shares | 12,882 | $7.72 | $99,449.04 |
DisclosureSEC source: 0001179110-21-003566 · edgar.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:43 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001209191-21-017940 · doc4.xml · derivative · entry 6 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:43 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 15,250 | $34.93 | $532,682.50 |
DisclosureSEC source: 0001209191-21-017940 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 72,269 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 22:43 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | Exercise / conversionCommon Stock | 20,000 | $26.58 | $531,600.00 |
DisclosureSEC source: 0001209191-21-017940 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 87,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:45 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 21,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-21-000011 · wf-form4_161048789174783.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,682 Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 10,000 | $34.27 | $342,738.00 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 10 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 F10 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $33.74 to $34.62. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,120 | $33.82 | $37,879.30 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 9 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 F9 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $33.63 to $33.905. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 7,441 | $32.97 | $245,338.70 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 8 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,120 F8 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $32.625 to $33.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 22, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,439 | $32.09 | $46,177.94 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 7 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,561 F7 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $31.6 to $32.5. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 10,000 | $30.35 | $303,521.00 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 6 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 F6 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $30.3505 to $30.3538. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 8,412 | $38.27 | $321,910.42 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 5 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $37.78 to $38.58. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 4,300 | $37.21 | $159,991.39 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,412 F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $36.77 to $37.765. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,864 | $36.03 | $103,190.78 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,712 F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $35.64 to $36.6. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 1,814 | $34.90 | $63,305.88 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,576 F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $34.53 to $35.41. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:41 UTC | Korro Bio, Inc. FREQ · Entity 6388 | SaleCommon Stock | 2,310 | $33.92 | $78,358.67 |
DisclosureSEC source: 0001127602-20-032250 · form4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,390 F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $33.50 to $34.46. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:07 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-20-064379 · doc4.xml · derivative · entry 8 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-06-14 F4 · kind: The reporting person transferred this option for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:07 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-20-064379 · doc4.xml · derivative · entry 7 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-06-14 F4 · kind: The reporting person transferred this option for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:07 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001209191-20-064379 · doc4.xml · derivative · entry 6 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-06-16 F4 · kind: The reporting person transferred this option for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:07 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001209191-20-064379 · doc4.xml · derivative · entry 5 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-06-16 F4 · kind: The reporting person transferred this option for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. F5 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:07 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftCommon Stock | 28,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064379 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 67,519 F1 · kind: The reporting person transferred these shares for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 21:07 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GiftCommon Stock | 28,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064379 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reporting person transferred these shares for no consideration to the Joel S. Marcus and Barbara A. Marcus Family Trust. Read SEC document |
| October 29, 2020 Filed Nov 3, 2020 02:50 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056497 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,360 F1 · kind: Gift to irrevocable trust. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:31 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 3,500 | $173.51 | $607,285.00 |
DisclosureSEC source: 0001035443-20-000239 · wf-form4_159786909148293.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,431 F2 · price: The shares were sold at prices ranging from $173.50 to $173.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:31 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 4,000 | $171.52 | $686,080.00 |
DisclosureSEC source: 0001035443-20-000239 · wf-form4_159786909148293.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,931 F1 · price: The shares were sold at prices ranging from $171.51 to $171.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 12, 2020 Filed Aug 12, 2020 21:49 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | SaleOrdinary Shares | 7,959 | $14.15 | $112,619.85 |
DisclosureSEC source: 0000899243-20-022166 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. F3 · price: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.93 to $14.32, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.